This document describes Syncrosome's capabilities for conducting preclinical studies using various animal models of central nervous system disorders. It lists models for Parkinson's disease, including those using haloperidol, 6-OHDA, and L-DOPA treatments. It also describes a stroke model using middle cerebral artery occlusion and models for assessing central nervous system pharmacokinetics. A wide range of techniques are mentioned, such as stereotactic surgeries, drug administrations, behavioral testing, sample collection and analysis, and methods for evaluating outcomes like neuroprotection and neuroinflammation.

1. SYNCROSOME
In Depth Efficacy Characterization CRO

2. Animal models Manipulation Read-outs
- Haloperidol
- Late 6-OHDA
- Early 6-OHDA
- L-DOPA
- STROKE
- Microdialysis
- CSF sampling
- All type of treatments
- Small molecules
- Immunization
- Nutraceuticals
- All routes of administration
- Ip, iv, sc, im
- Intranasal
- ICV / stereotactic injection
- Oral (gavage, food, water)
- Sample collection
- Brain – blood – CSF - organs
- Tissue preparation
- Total brain excixion
- Dissection of brain
- Free-floating brain sections
- Immunohistochemistry
- Neuroprotection
- Substantia Nigra
- Striatum
- Neuroinflammation
- Specific Biomarkers
- Biochemistry
- Neurotransmitters monitoring
- Behaviourand and Locomotor
activity
SYNCROSOME’S CNS ANIMAL MODELS

3. PARKINSON DISEASE’S MODELS

4. HALOPERIDOL-INDUCED CATALEPSY
MODELS : Haloperidol-induced catalepsy
SPECIES : Rats
TECHNIQUE : Haloperidol administration
Bar test
PARAMETERS : Time before removal of the 2 paws
REF. COMPOUNDS : L-DOPA

5. LATE STAGE MODEL FOR PARKINSON DISEASE
MODELS : 6-OHDA-induced akinesia
SPECIES : Rats
TECHNIQUE : Stereotaxic administration of 6-OHDA
PARAMETERS : Behavioural tests
Neuroprotection assays (ImmunoHistoChemistry)
REF. COMPOUNDS : L-Dopa

6. EARLY STAGE MODEL FOR PARKINSON DISEASE
MODELS : 6-OHDA-induced akinesia
SPECIES : Rats
TECHNIQUE : Specific administration of 6-OHDA
PARAMETERS : Neuroprotection and Neuroinflammation assays (IHC)
REF. COMPOUNDS : Nicotine, Riluzole and Q10 Coenzyme

7. L-DOPA INDUCED DYSKINESIA
MODELS : L-DOPA induced dyskinesia
SPECIES : Rats
TECHNIQUE : L-DOPA chronic administration
PARAMETERS : Dyskinesia parameters
REF. COMPOUNDS : Amantadine

8. STROKE

9. STROKE : MCAO (MIDDLE CEREBRAL ARTERY
OCCLUSION) MODEL
MODELS : Transient, Focal Ischemia
SPECIES : Rats
TECHNIQUE : - Intraluminal occlusion of middle
cerebral artery
PARAMETERS : MNSS Scoring, Locomotor and Behavioural tests,
IHC
REF. COMPOUNDS : MK801

10. CNS-PK

11. MODELS FOR OF THE BBB PASSAGE STUDIES
BRAIN REMOVAL : Evaluation of intra-tissular
concentration of the compound
(free and bound fraction)
CSF SAMPLING : Acute or chronic model of CSF
Sampling: CNS-PK of a compound in
the same animal during several days
MICRODIALYSIS : CNS-PK of a compound in the same animal
until 6 hours every 10 min
2 different sites of brain (free fraction)